Larimar Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
LRMR Nasdaq 2830 www.larimartx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Larimar Therapeutics, Inc.

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - Aug 4th, 2026 5:00 am
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Jul 15th, 2026 9:43 am
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 - Jul 8th, 2026 4:44 pm
Here’s What Citi Thinks About Larimar Therapeutics (LRMR) - Jul 3rd, 2026 7:13 am
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Jul 2nd, 2026 2:32 pm
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) - Jun 29th, 2026 8:00 am
Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know - Jun 29th, 2026 7:02 am
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp - Jun 29th, 2026 6:26 am
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia - Jun 29th, 2026 4:30 am
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia - Jun 26th, 2026 2:05 pm
Exploring 3 High Growth Tech Stocks in US Market - Jun 15th, 2026 5:39 am
Exploring US High Growth Tech Stocks This May 2026 - May 15th, 2026 5:38 am
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update - May 14th, 2026 5:00 am
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia - Apr 30th, 2026 2:05 pm
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Mar 27th, 2026 1:30 am
Larimar: Q4 Earnings Snapshot - Mar 19th, 2026 5:22 am
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 19th, 2026 5:00 am
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Mar 6th, 2026 8:26 am
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March - Mar 4th, 2026 2:05 pm
Larimar Therapeutics price target raised to $12 from $11 at Wedbush - Mar 4th, 2026 6:50 am